Aflibercept is among the recombinant proteins targeting the VEGF signaling pathway; Aflibercept is a soluble recombinant VEGFR fusion protein that inhibits multiple VEGF family members (i.e., VEGFA, VEGFB, and PIGF) which has been approved for the treatment of metastatic colorectal cancer [8]. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.